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Abstract
Background: In patients with BRAFV600 mutated unresectable stage IIIc or metastatic melanoma, molecular targeted
therapy with combined BRAF/MEK-inhibitor vemurafenib plus cobimetinib has shown a significantly improved progression-
free survival and overall survival compared to treatment with vemurafenib alone. Nevertheless, the majority of BRAFV600
mutation-positive melanoma patients will eventually develop resistance to treatment.
Molecular imaging with 18F-Fluorodeoxyglucose (18F-FDG) PET has been used to monitor response to vemurafenib in some
BRAFV600 mutated metastatic melanoma patients, showing a rapid decline of 18F-FDG uptake within 2 weeks following
treatment. Furthermore, preliminary results suggest that metabolic alterations might predict the development of resistance
to treatment. 18F-Fluoro-3′-deoxy-3’L-fluorothymidine (18F-FLT), a PET-tracer visualizing proliferation, might be more suitable
to predict response or resistance to therapy than 18F-FDG.
Methods: This phase II, open-label, multicenter study evaluates whether metabolic response to treatment with vemurafenib
plus cobimetinib in the first 7 weeks as assessed by 18F-FDG/18F-FLT PET can predict progression-free survival and whether
early changes in 18F-FDG/18F-FLT can be used for early detection of treatment response compared to standard response
assessment with RECISTv1.1 ceCT at 7 weeks.
Ninety patients with BRAFV600E/K mutated unresectable stage IIIc/IV melanoma will be included. Prior to and during
treatment all patients will undergo 18F-FDG PET/CT and in 25 patients additional 18F-FLT PET/CT is performed.
Histopathological tumor characterization is assessed in a subset of 40 patients to unravel mechanisms of resistance.
Furthermore, in all patients, blood samples are taken for pharmacokinetic analysis of vemurafenib/cobimetinib. Outcomes
are correlated with PET/CT-imaging and therapy response.
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Discussion: The results of this study will help in linking PET measured metabolic alterations induced by targeted therapy of
BRAFV600 mutated melanoma to molecular changes within the tumor. We will be able to correlate both 18F-FDG and 18F-
FLT PET to outcome and decide on the best modality to predict long-term remissions to combined BRAF/MEK-inhibitors.
Results coming from this study may help in identifying responders from non-responders early after the initiation of therapy
and reveal early development of resistance to vemurafenib/cobimetinib. Furthermore, we believe that the results can be
fundamental for further optimizing individual patient treatment.
Trial registration: Clinicaltrials.gov identifier: NCT02414750. Registered 10 April 2015, retrospectively registered.
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Background
Cutaneous malignant melanoma develops from melano-
cytes, which can either occur de novo or from a pre-ex-
isting lesion such as an acquired, congenital or
dysplastic nevus. Worldwide, the highest incidence in
melanoma is in Australia and New Zealand, but also in
Europe and North America incidence is rising [1]. In
2013, more than five thousand (5489) newly diagnosed
patients with skin melanoma were treated in the
Netherlands [2]. Fifteen to twenty percent of these
patients develop stage IV melanoma and in 2013 about
800 patients died from melanoma.
For many years, the only available systemic therapy was
the chemotherapeutic agent dacarbazine, resulting in poor
response rates (around 5–20%) and no significant survival
benefit. This changed in 2011 with the introduction of the
immune checkpoint inhibitor ipilimumab and inhibitor of
the MAP kinase pathway vemurafenib, anti-melanoma
agents that improved progression free and overall survival
of patients with advanced melanoma [3, 4]. After the
introduction of these revolutionary therapies the BRAF
inhibitor dabrafenib, MEK-inhibitors trametinib and cobi-
metinib, and the anti-PD1 antibodies nivolumab and
pembrolizumab were approved for the treatment of meta-
static melanoma. Despite the introduction of these
practice-changing drugs in the treatment of metastatic
melanoma a number of critical issues remains to be
settled. First, what is the optimal sequence of immuno-
therapy and targeted therapy? Second, can we predict and
overcome resistance against these agents?
Targeted cancer therapies include drugs that interfere
with oncogenic molecules involved in cancer cell growth
and survival. The Mitogen Activated Protein Kinase
(MAPK) pathway is a chain of proteins that in normal
cells regulates cell division, differentiation and secretion
through relaying extracellular signals from cell membrane
to nucleus via a cascade of phosphorylation events.
Dysregulation of the MAPK pathway plays a major role in
malignant transformation of cells. The BRAF kinase pro-
tein is one of the proteins responsible for regulating the
MAPK pathway. In many human cancers, dysregulation
of the MAPK pathway is caused by a mutation in the
BRAF gene. In melanoma, BRAF mutations account for
roughly 40–50% of all cases and is most common in
so-called non-chronic sun damage melanomas [5, 6]. The
most frequent BRAF mutation is the BRAFV600E muta-
tion, situated in the kinase domain of the protein, in which
a Glutamic acid is substituted for Valine at residue 600 in
ATP binding pocket [6, 7]. This BRAFV600 mutation
represents a unique target for cancer therapy and has led
to the development of several specific BRAF inhibitors,
amongst others vemurafenib. In melanoma patients, this
oral inhibitor of mutated BRAF protein only works in the
presence of a BRAFV600E or V600 K mutation; melan-
oma cells without this mutation are not inhibited.
Results from the randomized controlled phase III trial
(BRIM3) comparing vemurafenib to standard dacarbazine
chemotherapy in newly diagnosed patients with BRAFV600E
mutation positive metastatic melanoma revealed a median
PFS of 6.9 months for vemurafenib and 1.6 months for
dacarbazine (HR 0.26; 95% CI, 0.20–0.33; p < 0.0001). An
objective response rate of 48.8% was found in the vemurafe-
nib group, compared to a response rate of 5% with dacarba-
zine. In addition, this study showed a significant survival
benefit in favor of vemurafenib [4, 8].
These improved overall and progression-free survival
have led to approval of vemurafenib by the Food and Drug
Administration (FDA) on August 17, 2011, as a first line
treatment in patients with BRAF-mutated unresectable or
metastatic melanoma. On May 29, 2013, also BRAF inhibi-
tor dabrafenib was approved by the FDA, based on demon-
stration of improved PFS in a phase III multi-center,
international, open-label, randomized controlled trial [9].
With these highly encouraging data, however, new
problems appeared. The biggest dilemma is the relative
short duration of BRAF inhibitor-induced responses due
to the development of resistance to these drugs, which
eventually occurs in all treated patients. However, while
these mechanisms appear to be much more pleiotropic
than expected, on an individual basis we are unable to
forecast when resistance will set in. Another problem is
that even though the majority of patients benefit from
the treatment, still a number of patients do not benefit
at all as progression of the disease continues after the
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initiation of therapy. At this point it is not possible to
select patients who will benefit from this therapy in
advance or early after initiation of therapy.
The major resistance mechanism to BRAF inhibition is
reactivation of the MAPK pathway, either due to amplifica-
tion of the mutated BRAF gene, occurrence of splice vari-
ants of mutated BRAF, activating MEK mutations,
activating RAS mutations or epigenetic alterations leading
to activation of the MAPK or PI3K pathway [10, 11]. This
has led to the development of MEK-targeted therapies that
target this pathway further downstream. Although in a
phase III study a MEK inhibitor has demonstrated an OS
benefit over chemotherapeutic drugs in patients with ad-
vanced melanoma containing a BRAFV600E mutation [12],
the clinical usefulness of MEK inhibitors as single agent in
the treatment of advanced melanoma is uncertain. This is
mainly because the response rates with MEK inhibitors do
not reach those of selective BRAF inhibitors [8, 9].
Combined BRAF and MEK inhibition
Based on the mechanisms of resistance to BRAF inhib-
ition combining BRAF inhibitors with MEK inhibitors
was investigated. In three randomized phase III trials
combined BRAF- and MEK inhibition out-performed
BRAF inhibitor monotherapy.
In the COMBI-d study patients with advanced melan-
oma were randomly assigned to receive dabrafenib plus
trametinib or dabrafenib plus placebo as a first-line treat-
ment. Median PFS provided only a minor advantage com-
pared to monotherapy (9.3 vs. 8.8 months; p = 0.03). In
addition, combined BRAF and MEK inhibition resulted in
a 25% relative reduction in the risk of disease progression
compared with dabrafenib alone, as well as a significant
higher response rate (67 vs. 51%; p = 0.002) [13].
In May 2015, Long et al. published follow-up data on
median OS, which was 25.1 months for patients in the
dabrafenib plus trametinib group versus 18.7 months for
patients in the dabrafenib-only group (HR 0.71, 95% CI
0.55–0.92; p = 0.0107). Based on 301 events, median
PFS was 11.0 months (95% CI 8·0–13·9) in the dabrafe-
nib and trametinib group and 8.8 months (5.9–9.3) in
the dabrafenib only group (HR 0.67, 95% CI 0.53–0.84;
p = 0.0004) [14].
In the COMBI-v study 704 patients with BRAF mutated
metastatic melanoma were randomly assigned to receive
either a combination of dabrafenib plus trametinib or
vemurafenib alone as a monotherapy. The primary end-
point was OS, the study was stopped early because at the
interim analysis OS was longer in patients treated with the
combination compared to patients given the monotherapy
(median OS not reached vs. 17.2 months), as well as
higher PFS (11.4 vs 7.3 months; HR 0.56, 95% CI 0.46–
0.69; p < 0.001), duration of response (13.8 vs. 7.5 months)
and response rate (64 vs. 51%; p < 0.001) [15].
In the 3rd phase III study, coBRIM, untreated BRAF-
mutant patients were randomized to receive BRAF in-
hibitor vemurafenib plus MEK inhibitor cobimetinib or
vemurafenib plus placebo: combination therapy resulted
in improved PFS (9.9 vs. 6.2 months; HR 0.51, 95% CI
0.39–0.68; p < 0.001), 9-month OS rate (81.1 vs. 72.5%)
and response rate (68 vs. 45%; p < 0.001) [16]. In an up-
dated report presented at the SMR 2015 an improved
PFS (12.3 vs 7.2 months, p < 0.001) and overall survival
(22.3 vs 17.4 months, p = 0.005) was shown in favour of
the combined vemurafenib plus cobimetinib arm [17].
Based on these clinical trials revealing the clinical
benefit of the combination the FDA approved in
November 2015 vemurafenib plus cobimetinib as well as
dabrafenib plus trametinib for the treatment of patients
with unresectable or metastatic melanoma with BRAF
V600E or V600K mutations.
Positron emission tomography
Positron Emission Tomography / Computed Tomography
(PET/CT) is a nuclear medicine technique that produces a
three-dimensional image of functional processes in the
body combined with anatomical mapping by means of CT.
Depending on the type of tracer, a diverse of molecular pro-
cesses can be visualized such as glucose metabolism, prolif-
eration or hypoxia.
18F-Fluorodeoxyglucose (18F-FDG) is the radiotracer
mostly used in clinical application of PET. 18F-FDG is a
radiolabelled glucose analogue that replicates the glucose
metabolism. Unlike glucose, 18F-FDG is phosphorylated,
causing a stop to further metabolism and, consequently,
trapped in the cell. Since the glucose metabolism is
higher in tumor cells than in surrounding normal cells,
malignant lesions show enhanced 18F-FDG uptake on a
PET-scan. 18F-FDG PET/CT has been widely studied in
staging, restaging and response assessment in almost
any type of malignant tumors. In the guidelines of Non
Small Cell Lung cancer, 18F-FDG PET/CT has become
one of the most important tools in staging mediastinal
lymph node involvement. Several meta-analyses revealed
a higher sensitivity and specificity with 18F-FDG PET
compared to diagnostic CT [18–21].
Generally, the utility of 18F-FDG PET imaging in melan-
oma patients depends on the stage of the tumor. In Stage I
and II melanoma, 18F-FDG PET appears to have no add-
itional value since micrometastases are missed because 18F-
FDG PET cannot detect small tumor volumes [22, 23].
Even in patients with proven tumor positive sentinel lymph
nodes, staging with 18F-FDG PET results in a high percent-
age of false positives and false negatives [24, 25]. On the
contrary, 18F-FDG PET does seem to be valuable in Stage
III and IV melanoma, especially in detecting distant metas-
tases and recurrence as well as in monitoring therapy
response. At the NKI, Aukema et al. showed in 70 patients
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with palpable lymph node metastases an 87% sensitivity
and 98% specificity in the detection of other metastases
[26]. In this study, 18F-FDG PET/CT led to a change in
treatment in 37% of patients. Though routinely CT is
performed for detecting distant metastases in stage III
melanoma, 18F-FDG PET/CT has shown superior perform-
ance compared to CT alone [27, 28]. Sensitivity and specifi-
city of 18F-FDG PET/CT was 86 and 91% respectively
whereas for CT alone a sensitivity of 65% and specificity of
78% was reported. For the detection of metastatic disease
in the brain, liver and bone, MRI is superior to 18F-FDG
PET/CT [29]. Therefore, a combination of 18F-FDG PET/
CT and MRI is the most efficient manner to perform whole
body surveillance in high-risk stage III and IV melanoma.
Response monitoring with PET
For monitoring therapy response in unresectable stage IIIc
or metastatic melanoma, contrast enhanced CT (ceCT) is
the current standard imaging tool. Unfortunately, reduction
in tumor size cannot be assessed within days after the
initiation of therapy and anatomic size does not provide
information about the development of therapy response or
resistance at a molecular level. It has been clearly demon-
strated that alterations in metabolism occur earlier than
anatomical size reduction after the initiation of therapy.
PET imaging is a sensitive method to detect alterations in
cell metabolism, even within 15 days after the start of
therapy [30]. By detecting these metabolic alterations, it is
suggested that responders can be distinguished from non--
responders at an earlier phase compared with anatomical
imaging with ceCT [31]. This way, unnecessary expensive
treatment with combined BRAF/MEK inhibition and its
side effects may be prevented in patients who will not bene-
fit from this therapy.
18F-FDG PET in monitoring response assessment has
been investigated in many tumors, but has not been
studied systematically in metastatic melanoma patients,
due to the lack of an efficacious treatment. With the
promising results in OS and PFS in patients treated with
combined BRAF/MEK inhibition, response monitoring
becomes a topic of high interest. Sondergaard et al. stud-
ied the effect of vemurafenib in different in-vitro cell
lines, all with a BRAFV600 mutation [32]. They demon-
strated a different sensitivity to PLX4032 in all ten cell
lines, three of these cell lines even showing resistance.
Inhibition of 18F-FDG uptake in the cell lines was more
profound in the sensitive cell lines than in the resistant
cell lines, suggesting that 18F-FDG PET can be used as a
non-invasive imaging technique to distinguish between
sensitive and resistant tumors.
In a dose-escalation study of vemurafenib, 18F-FDG
PET/CT was performed in a selective group of patients
at baseline and on day 15 of the first 4 weeks of therapy
[30, 33]. 18F-FDG PET/CT showed a decrease in uptake
in all patients, corresponding with therapy response.
Furthermore, preliminary results in literature suggest a
positive association between the level of decline in meta-
bolic activity in the first 2 weeks after the initiation of
therapy and PFS and OS [31]. In a preclinical study it
was demonstrated that in mutant melanomas treated
with vemurafenib and the MEK inhibitor cobimetinib
(GDC-0973), metabolic imaging with 18F-FDG PET ap-
peared to be a good biomarker of both early response
assessment and acquired resistance [34]. If clinically vali-
dated, one could switch metabolic non-responders to
early additional therapy, guided by phosphoprotein and/
or DNA mutation profiles, with other targeted therapies
(e.g. ERK-inhibitors or PI3-kinase inhibitors) or change
to immunotherapy.
18F-FDG versus 18F-FLT PET
As mentioned before, BRAF inhibition interferes in the
MAPK pathway through inhibition of oncogenic mutated
BRAFV600. As a consequence, cell proliferation is altered.
18F-fluoro-3′-deoxy-3′-L-fluorothymidine (18F-FLT) is a
tracer developed for PET, which can visualize cell prolifera-
tion in vivo. In the S phase, 18F-FLT is phosphorylated to
3′-fluorothymidine monophosphate by thymidine kinase 1,
after which it is trapped in the cell due to its negative
charge. Thus, 18F-FLT accumulates in proliferating tissue
and the uptake is reduced in cells that are in the growth-
arrested phase [35]. Compared to 18F-FDG, 18F-FLT has a
lower overall uptake and higher background activity in
liver and bone marrow [36]. The use of 18F-FLT PET in on-
cology should be considered a powerful addition to
18F-FDG PET, providing additional information that could
be useful in predicting prognosis, planning treatment and
monitoring response [37]. Increased DNA synthesis is
potentially more tumor-specific than high glucose metab-
olism and may correspond more directly with tumor
aggressiveness and response to therapy. Therefore, it is
likely to assume that 18F-FLT could be of additional value
in stage III/IV melanoma.
Only four studies have investigated in vivo the value of
18F-FLT in melanoma compared to 18F-FDG, and only
one of these response to anti-cancer vaccination was
studied [38]. In two studies, 18F-FLT appeared to be a
good tracer in the evaluation of response to therapy with
BRAFV600 mutation in mice [39, 40]. In addition, in the
study by Solit et al., 18F-FLT seemed more sensitive to
treatment response compared to 18F-FDG (mean decline
of uptake of 43% in 18F-FLT versus 16% in 18F-FDG). In
both studies only a MEK inhibitor was used. Response
assessment of BRAFV600E inhibitors in preclinical
models of colorectal cancer showed also that 18F-FLT is
a sensitive predictor, perhaps even better than 18F-FDG
[41]. Geven et al. evaluated these tracers for response
assessment of a BRAFV600E inhibitor in mice with
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melanoma xenografts. They concluded that only 18F-
FDG PET is useful as an imaging biomarker for the
evaluation of early response [42]. No studies are avail-
able in which a BRAF inhibitor plus MEK inhibitor is
used to compare 18F-FLT to 18F-FDG in response
assessment.
Genomics and phosphoproteomics in melanoma
The underlying mechanism of resistance to BRAFV600
inhibitors that have been discovered to date lies in alter-
ations in, and parallel to, the MAPK pathway. However,
although this compound, or drugs inhibiting other com-
ponents within this pathway, initially reduces tumor bur-
den dramatically, eventually virtually all melanomas
become resistant and patients succumb to the disease.
Drug resistance has therefore become subject to intense
study, which has led to the identification of a plethora of
mechanisms. For example, several mutations located in
the MAPK pathway have been identified, including the
C121S mutation in MEK1, Q61K in NRAS, K117 N in
KRAS and a gatekeeper mutation T529 in BRAFV600
([10, 11] and references therein). In addition, long-term
treatment with BRAF inhibitor has been shown to in-
duce switching between RAF isoforms, amplification of
BRAFV600 or expression of an alternative 61-kDa RAF
splice variant lacking the RAS-binding domain. Other
mechanisms, not involving the MAPK-pathway, have
been found as well, like upregulation of IGF-1R, EGFR,
PDGFRβ, FOXP3 or FGFR3 signaling [43–45]. Overex-
pression of COT, Cyclin D1 and amplification of MET
and CTNNB1 can confer resistance to vemurafenib, too
[10, 11]. Lastly, the stroma can play a decisive role in ac-
quiring resistance, as it was found that upregulation of
HGF by the surrounding stroma occurs during resist-
ance [46, 47].
Phosphoproteomics allows for unbiased phosphopro-
tein profiling and thereby may yield novel insights into
aberrantly activated signaling pathways in cancer cells
and tissues in situ. Therefore, phosphoproteomics may
identify the above-mentioned mechanisms including al-
terations in MAPK-pathway activity and may uncover
additional, novel mechanisms. Recent phosphoproteo-
mics studies in melanoma cell lines have investigated
basal and kinase inhibitor driven adaptive signaling, and
have provided insight into the molecular nature of the
(combinatorial) response and resistance [48–52].
Pharmacokinetics
As mentioned earlier, despite proven efficacy of BRAF
inhibitors in BRAFV600 mutation-positive metastatic
melanoma, responses remain temporary.
Failure arises most likely from induction of resistance
to these agents but pharmacokinetic variability may con-
tribute as well. The ease of oral administration enables
patients to get their drug regimen in an outpatient set-
ting, which is more patient friendly. However, oral ad-
ministration also entails the possibility of variable drug
exposure due to patient non-compliance, drug interac-
tions with co-medication and variability in oral drug
availability.
The relation between treatment outcome (adverse
effects and/or treatment failure) and dose has been de-
scribed in clinical studies. However plasma concentra-
tions have been described only in a single phase I
clinical trial on day one and day 15. These results
showed large interpatient variability [33]. Pharmacoki-
netic variability (both interpatient and intrapatient) may
be an important factor for treatment outcome, but more
data should be collected.
Methods/design
Trial design
The Reposit-study is a national multi-center open-label
single arm explorative phase II clinical study.
Patient population
BRAFV600E or BRAFV600K mutation-positive patients
with unresectable locally advanced or metastatic melan-
oma will be included in the trial. Inclusion and exclusion
criteria are listed in detail in Table 1, written informed
consent is required for inclusion.
Study objectives
The primary aims of this study are to evaluate
whether changes in 18F-FDG and/or 18F-FLT PET in
the first 7 weeks can predict progression-free survival
and whether early changes (at 2 weeks) in 18F-FDG
and/or 18F-FLT PET can be used for early detection
of response to treatment with combined BRAF/MEK
inhibitor vemurafenib plus cobimetinib compared to
standard response assessment with ceCT according to
RECIST v1.1 at 7 weeks.
Several secondary aims are defined in this study.
The level of target inhibition is studied to whether it
can predict the type (CR/PR, SD or PD) and duration
of response. Molecular mechanisms of resistance will
be elucidated by integrating global protein phosphor-
ylation, genomic and cancer mutation data. The cor-
relation between PET imaging and several key tumor
characteristics at different levels is studied through a)
measurements of BRAF signaling activity by immuno-
histochemistry (including pERK), b) analyzing DNA
mutation spectrum by next-generation sequencing, c)
analyzing gene expression patterns by microarray
analysis and d) analyzing protein phosphorylation
patterns by mass spectrometry-based phosphoproteo-
mics. We will investigate whether differences in global
phosphoprotein (including markers of BRAF pathway
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activity) and mutation profiles occur between sensitive
and matched resistant tumor lesions and whether
these profiles can predict benefit from vemurafenib/
cobimetinib and resistance. Furthermore, we will in-
vestigate whether differences in protein phosphoryl-
ation patterns can be identified between pre and post
treatment tumor biopsies, and whether the pre-
treatment patterns would bare predictive power for
response to treatment. The correlation between the
pharmacokinetics of vemurafenib/cobimetinib and
PET imaging is studied as well as the correlation be-
tween pharmacokinetics and therapy response. Finally,
various quantitative measures of radiotracer uptake
from baseline upon PET imaging are studied for pre-
dicting the type (CR/PR, SD or PD) of response,
progression-free survival and overall survival.
Study endpoints
Two primary endpoints are defined: (1) Changes in Stan-
dardized Uptake Value (SUV) of 18F-FDG and 18F-FLT
PET, assessed on a continuous scale and categorized using
PERCIST criteria, (2) Progression-free survival.
The secondary endpoints are as follows:
 Diagnostic accuracy of metabolic tracer uptake on
PET in responders and non-responders.
 Glycolytic Index, Metabolic Tumor Volume and %
Injected Dose of 18F-FDG/FLT on PET.
 Immunohistochemical analysis of tumor tissue in
responders and non-responders.
 Changes of DNA in tumor tissue as measured by
DNA deep sequencing analysis.
 Changes of RNA in tumor tissue as measured by
RNA expression analysis.
 Changes of phosphoproteomic profiles in tumor
tissue measured by nano-liquid chromatography
coupled to tandem mass spectrometry
(nanoLC-MS/MS).
 Changes in vemurafenib and cobimetinib drug
concentrations in plasma as measured by a validated
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Disease-Specific Inclusion Criteria:
• Histologically confirmed melanoma, either unresectable stage IIIc or stage IV
metastatic melanoma, as defined by AJCC 7th edition.
• Naïve to treatment for locally advanced unresectable or metastatic disease
(i.e., no prior systemic anti-cancer therapy for advanced disease; stage IIIc
and IV). Prior immunotherapy
(including ipilimumab) is allowed.
• Documentation of BRAFV600E or BRAFV600K mutation-positive status in
melanoma tumor tissue.
• Measurable disease per RECIST v1.1, which are accessible to biopsies.
• Biopsy lesion is within scan reach of contrast enhanced CT and PET/CT.
• ECOG performance status of 0 or 1.
• Consent to undergo tumor biopsies of accessible lesions.
Cancer-Related Exclusion Criteria:
• History of prior RAF or MEK pathway inhibitor treatment.
• Palliative radiotherapy, major surgery or traumatic injury
within 14 days prior to the first dose of study treatment.
• Active malignancy other than melanoma that could potentially
interfere with the interpretation of efficacy measures.
Exclusion Criteria Based on Organ Function:
• History of or evidence of retinal pathology on ophthalmologic
examination that is considered a risk factor for neurosensory
retinal detachment, retinal vascular occlusion, or neovascular
macular degeneration.
• History of clinically significant cardiac dysfunction, including
current unstable angina, symptomatic congestive heart failure
(NYHA classII), history of congenital long QT syndrome or mean
QTcF >450 msec at
baseline or uncorrectable abnormalities in serum electrolytes,
uncontrolled hypertension ≥ Grade 2, left ventricular ejection
fraction (LVEF) below
institutional lower limit of normal (LLN) or below 50%.
• Patients with active CNS lesions, except when all known CNS
lesions have
been treated with stereotactic therapy or surgery, AND there
has been no
evidence of clinical and radiographic disease progression in the
CNS for ≥3 weeks after radiotherapy or surgery.
General Inclusion Criteria:
• Male or female patient aged ≥18 years.
• Able to participate and willing to give written informed consent.
• Life expectancy ≥12 weeks.
• Adequate hematologic, hepatic and renal function.
• Use of adequate contraception during the course of this study and
for at least 6 months after completion of study therapy.
• Negative serum pregnancy test in women of childbearing potential.
• Absence of any psychological, familial, sociological, or geographical
condition that potentially hampers compliance with the study
protocol and follow-up after treatment discontinuation schedule.
General Exclusion Criteria:
• Current severe, uncontrolled systemic disease.
• History of malabsorption or other condition that would interfere
with absorption of study drugs.
• Pregnant, lactating, or breast-feeding.
• Unwillingness or inability to comply with study and follow-up
procedures.
• St. John’s wort or hyperforin (potent cytochrome P450 CYP3A4
enzyme inducer) and grapefruit juice (potent cytochrome P450
CYP3A4 enzyme
inhibitor) are prohibited at least 7 days prior to initiation of and
during treatment.
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Liquid Chromotography tandem Mass Spectrometry
assay.
 Overall Survival.
 ECOG Performance status.
Overview of study design
This national multicenter prospective clinical phase II
study will include approximately 90 BRAFV600E or
BRAFV600 K mutation-positive patients with unresect-
able locally advanced or metastatic melanoma. All pa-
tients included in the study will be treated with
vemurafenib 960 mg BID plus cobimetinib 60 mg QD.
The study is composed of 4 periods:
 Screening Period during which screening procedures
will take place in order to meet the inclusion
criteria,
 Baseline Period during which baseline study
procedures will take place (18F-FDG/18F-FLT PET,
Pharmacokinetic (PK) blood samples, tissue
sampling),
 Treatment Period during which patients are treated
with vemurafenib plus cobimetinib and during
which study procedures will take place,
 Follow-up Period during which late side effects are
monitored after end of treatment.
During the Screening Period, Baseline Period and
Treatment Period, patients are considered ‘on study’;
during Follow-up Period, patients are considered ‘off
study’.
Laboratory assessments, physical examination, derma-
tologic examination, ophthalmology examination and
cardiac evaluation will take place during the study to
monitor safety and side effects of vemurafenib and
cobimetinib.
All 90 patients will undergo 18F-FDG PET prior to
treatment, 2 weeks after the initiation of therapy, at the
end of the seventh week and at progression to compare
to regular ceCT.
Additional PET with 18F-FLT will be performed at
baseline, 2 weeks and at progression, PK blood samples
will be collected for drug level monitoring of vemurafe-
nib/cobimetinib and biopsies are taken for histopatho-
logical tumor characterization.
To answer all main and secondary objectives, 18F-FLT
PET and tissue samples are only needed in a subset of
patients. Therefore, this cohort is divided into three
substudies:
 Substudy 1: 25 patients undergoing 18F-FDG PET,
PK blood sampling, tumor
biopsies and 18F-FLT PET,
 Substudy 2: 15 patients undergoing 18F-FDG PET,
PK blood sampling and tumor
biopsies,
 Substudy 3: 50 patients undergoing 18F-FDG PET
and PK blood sampling.
Patients will be offered to participate in either one of the
three substudies, depending on the wish and conditions of
the patient. There is no randomization or blinding, all
patients will receive the same treatment. Figure 1 shows a
time schedule of the most important procedures.
Study procedures
The schedule of study assessments and procedures are
detailed in Table 2.
Screening and baseline period
After signing informed consent, patients will undergo
screening procedures that include testing for the
BRAFV600 mutation; laboratory tests (hematology, chemis-
tries, LFTs); 12-lead ECG; left- ventricular function evalu-
ation (MUGA), contrast-enhanced magnetic resonance
imaging (MRI) or CT scan of the brain; contrast-enhanced
CT of the chest, abdomen, and pelvis; and dermatologic
assessments. After registration patients will undergo base-
line procedures prior to the Treatment Period, including
18F-FDG PET, 18F-FLT PET (Substudy 1), PK blood
sampling and tissue sampling (Substudy 1 and 2).
Study medication
During the Treatment Period vemurafenib will be taken
orally at a starting dose of 960 mg BID, starting on Day
1 to Day 28 of each 28-day treatment cycle. Cobimetinib
will be taken orally 60 mg once daily starting on Day 1
to Day 21 of each 28-day treatment cycle.
All patients will be closely monitored for safety and
tolerability during all cycles of therapy, at the end-of-
study treatment visit, and during the follow-up period.
Treatment will continue until disease progression, death,
unacceptable toxicity, or withdrawal of consent, which-
ever occurs earliest.
In patients with confirmed progressive disease accord-
ing to RECIST v1.1 study treatment is discontinued
when no benefit for the patient is expected anymore.
Response assessment
Tumor response will be evaluated with ceCT scans of
neck, thorax, abdomen and pelvis according to RECIST
v1.1. Any evaluable and measurable disease must be docu-
mented at screening and re-assessed at each subsequent
tumor evaluation. The ceCT scans are performed at base-
line, 2 weeks after start study medication, at the end of the
seventh week, every 8 weeks thereafter and at progression
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following standard protocol. CT/MRI scans may be
repeated at any time if progressive disease is suspected.
18F-FDG and 18F-FLT PET imaging
In all 90 patients 18F-FDG PET scans are performed at
baseline, Day 15 of Cycle 1, Day 21 of Cycle 2 and at
progression. In 25 patients additional 18F-FLT PET scans
are performed at baseline, Day 14 of Cycle 1 and at pro-
gression. Participating PET imaging sites must have the
EARL FDG-PET/CT accreditation prior to the start of
the study, and perform the PET scans to meet the stand-
ard requirements indicated in the European Association
of Nuclear Medicine (EANM) guideline ‘FDG PET and
PET/CT: EANM procedure guideline for tumour PET
imaging: version 1.0’ [53]. All PET/CT scans are DICOM
sent for central reviewing. All images will be assessed
visually to identify sites of increased uptake. For quanti-
fication, a software package is used, which is developed
for the specific purpose of quantifying PET images [54].
In all images, standardized uptake values (SUV) will be
calculated for both 18F-FDG and 18F-FLT PET studies of
sites showing the highest uptake. To evaluate and correl-
ate both PET studies, but also to correlate the results of
follow-up studies, a low-dose CT scan for attenuation
correction will be used to make a head to head compari-
son between the uptake at different sites feasible.
Blood samples for pharmocokinetics
At baseline, Day 15 of Cycle 1 and at progression blood will
be collected just before intake of the morning dose of
vemurafenib and cobimetinib for pharmacokinetic purpose.
In a subset of patients treated in the Netherlands Can-
cer Institute (approximately n = 25), blood samples for a
whole PK curve (pre-dose, 1 h, 2 h, 3 h, 4 h, 6 h and 8 h
post-dose) will be collected on Day 15 of Cycle 1.
Blood samples for DNA sequencing
A peripheral blood sample is obligated for all patients
who will undergo histological biopsy for DNA sequen-
cing. Therefore, 1x10mL blood will be drawn at baseline
and at the time of progression.
Tissue sampling for tumor characteristics
To evaluate the extent of inhibition of mutant BRAF, we
will monitor the activity of the pathway in tumor tissue
samples of 40 patients. Easily accessible progressive
target lesions according to RECIST v1.1 will be biopsied
before treatment, during treatment (t = 2 weeks) and at
the time of proven progression. Tumor biopsies will be
partly frozen or formalin fixated. Frozen tissue will be
used for RNA extraction for RNA sequencing, genomic
DNA extraction, next-generation sequencing and for
phosphoproteomics, formalin fixed paraffin embedded
material will be used for immunohistochemic analysis.
Monitoring adverse events
The NCI Common Terminology Criteria for Adverse
Events (CTCAE) v4.0 will be used to characterize the tox-
icity profile of the study treatments on all patients. ECG
assessments will be performed at screening, on Day 15 of
Cycle 1, Day 1 and 21 of Cycle 2, Day 1 (± 3 days) of Cycle
3 and 5 and then on Day 1 (± 3 days) every 3 treatment
cycles thereafter (Cycles 8, 11, 14, etc.). Dermatologic
Fig. 1 Study design scheme
van der Hiel et al. BMC Cancer  (2017) 17:649 Page 8 of 13
Ta
b
le
2
Sc
he
du
le
of
as
se
ss
m
en
ts
an
d
pr
oc
ed
ur
es
Pe
rio
d
Sc
re
en
in
g
Ba
se
lin
e
st
ud
y
pr
oc
ed
ur
es
Ve
m
ur
af
en
ib
/
C
ob
im
et
in
ib
Tr
ea
tm
en
t
Pe
rio
d
Fo
llo
w
-u
p
af
te
r
tr
ea
tm
en
t
C
yc
le
W
ith
in
28
da
ys
be
fo
re
st
ar
t
th
er
ap
y
W
ith
in
14
da
ys
be
fo
re
st
ar
t
th
er
ap
y
C
yc
le
1
C
yc
le
2
C
yc
le
3
C
yc
le
4
C
yc
le
5
C
yc
le
6
C
yc
le
7+
A
t
pr
og
re
ss
io
n
(E
oS
)
Ev
er
y
12
w
ee
ks
D
ay
1
14
15
1
21
1
(±
3)
1
(±
3)
1
(±
3)
1
(±
3)
1
(±
3)
W
ith
in
7
da
ys
(o
n
th
er
ap
y)
In
-
an
d
ex
cl
us
io
n
cr
ite
ria
X
M
ed
ic
al
hi
st
or
y
an
d
de
m
og
ra
ph
ic
s
X
In
te
rv
al
m
ed
ic
al
hi
st
or
y
X
X
X
X
X
X
X
X
X
X
X
Ph
ys
ic
al
ex
am
in
at
io
n
X
X
X
X
X
X
X
X
X
X
X
X
Vi
ta
ls
ig
ns
(T
em
p,
H
R,
RR
)
X
X
X
X
X
X
X
X
X
Pr
eg
na
nc
y
te
st
(if
in
di
ca
te
d)
X
D
er
m
at
ol
og
ic
ex
am
in
at
io
n
X
X
X
X
X
O
ph
th
al
m
ol
og
ic
ex
am
in
at
io
n
if
in
di
ca
te
d
M
U
G
A
sc
an
X
X
X
X
X
12
-le
ad
el
ec
tr
oc
ar
di
og
ra
ph
y
(E
C
G
)
X
X
X
X
X
X
X
X
C
on
tr
as
t
En
ha
nc
ed
C
T
(C
EC
T)
X
X
X
X
X
X
X
X
EC
O
G
pe
rfo
rm
an
ce
st
at
us
X
X
X
X
X
X
X
X
X
X
X
X
Bl
oo
d
sa
m
pl
es
X
X
X
X
X
X
X
X
X
X
X
In
fo
rm
ed
co
ns
en
t
X
PK
bl
oo
d
sa
m
pl
e
X
X
X
D
N
A
bl
oo
d
sa
m
pl
e
(S
ub
st
ud
y
1
an
d
2)
X
X
18
F-
FL
T
PE
T
(S
ub
st
ud
y
1)
X
X
X
18
F-
FD
G
PE
T
X
X
X
X
Tu
m
or
bi
op
sy
(S
ub
st
ud
y
1
an
d
2)
X
X
X
A
dv
er
se
ev
en
ts
X
X
X
X
X
X
X
X
X
X
X
St
ar
t
ve
m
ur
af
en
ib
co
bi
m
et
in
ib
X
X
=
A
ss
es
sm
en
t/
pr
oc
ed
ur
e
pe
rf
or
m
ed
to
m
ee
t
th
e
ob
je
ct
iv
es
of
th
e
st
ud
y,
X
=
A
ss
es
sm
en
t/
pr
oc
ed
ur
e
pe
rf
or
m
ed
to
m
on
ito
r
ve
m
ur
af
en
ib
/c
ob
im
et
in
ib
tr
ea
tm
en
t
van der Hiel et al. BMC Cancer  (2017) 17:649 Page 9 of 13
assessment will be performed at the beginning of Cycle 2
and then every 3 treatment cycles (± 3 days) thereafter
(Cycles 5, 8, 11, etc.). Ophthalmologic examination is
performed during treatment on suspicion of ocular
toxicity. Left-ventricular function evaluation (MUGA) is
evaluated throughout the study.
End of study and follow-up
The study will end when all patients enrolled have been
followed for at least 3 years, withdrawal of consent, lost
to follow-up, or the Sponsor decides to end the trial,
whichever occurs first.
Patients may continue on study treatment until the devel-
opment of progressive disease, unacceptable toxicity, and/
or consent withdrawal. Patients who discontinue study
treatment for any reason will be followed for development
of squamous cell carcinoma, followed for disease progres-
sion and followed for survival until death, withdrawal of
consent, or they are lost to follow-up.
Statistical methods
Sample size calculation
Since 18F-FDG-PET scans are made at multiple time
points (including baseline), the value of changes in meta-
bolic activity can be studied in relation to overall
response and time related endpoints.
There is a lack of evidence-based data in the assessment
of therapy response and therapy resistance using 18F-FDG
or 18F-FLT PET in patients with unresectable stage IIIc or
metastatic melanoma treated with a BRAF inhibitor. Con-
sequently, no robust power calculations can be performed
to estimate samples sizes. However, given some feasibility
aspects, some assumptions can be made about potential
results and expected outcome. Based on recent publica-
tions [55, 56], it is expected that the PFS will be about
9 months. Assuming a hazard ratio of 0.5 or smaller and a
50–50 distribution in 18F-FDG PET positive and negative
patients (either using the median or using the partial
metabolic response of 25% reduction in the SUVmax) we
can infer what median we would obtain.
Given the assumptions, the poor risk group would have
a median PFS of 6.5 months and the good risk group a
median of about 13 months. Assuming exponential
survival, 18 months of accrual and another 18 months of
follow-up (after the last patient has been enrolled), we
would need to observe 66 events and 90 patients to enroll
into the study (alpha 5% 2 sided and power 80%).
However, it should be stressed that these are assump-
tions and the nature of the study is explorative.
Experience with 18F-FLT is limited for monitoring
response. Therefore, 18F-FLT will be ‘screened’ for its value
by studying the association with 18F-FDG and CT in rela-
tion to response and outcome parameters. A review of
studies looking at the value of PET in relation to response
in various types of cancer, the average number of patients
was 29 (data not shown, but available on request). The
number of 25 patients is therefore considered both feasible
and sufficiently valuable.
Important issues to solve in this series of patients are to
develop a sensitive cut- off value for metabolic response
(which may be different than the median or the cut-off for
metabolic response found in other diseases), the associ-
ation or potentially added value of the 18F-FLT PET-scan
and the association with (high-dimensional) biomarkers.
Biopsies will be performed in a subset of 40 patients.
This number is based on the paper of Dobbin and Simon
2007 in which sample sizes are calculated for building
predictors [57]. The simulations indicated that with 2 dif-
ferentially expressed genes, and 40 patients an effect size
(2δ/σ) of 1.5 or more and with one differentially expressed
gene, an effect size of 1.7 or better could be obtained.
Statistical analysis
Patient demographic data, tumor characteristics and
data derived from the scans and biopsies will be
described in frequency tables. In general, for continuous
variables, mean, standard deviation, median, IQR and
minimum and maximum will be given. Categorical
variables will be presented with 95% confidence intervals
whenever relevant (i.e. response).
SUV-parameters (mean, 3D peak, max) for 18F-FDG
and 18F-FLT will be measured on a continuous scale and
categorized or dichotomized using various rules available
(PERCIST, and published disease specific rules). CT will
be expressed according to RECIST v1.1. Linear-by-linear
non-parametric analysis will be used for associations
between 18F-FDG and 18F-FLT PET imaging and pharma-
cokinetics parameters and ceCT. Logistic regression and
ROC-analysis may be applied to investigating the continu-
ous parameters in association with response (CR + PR)/
non response or clinical benefit (CR + PR + SD)/progres-
sion. Accuracy measures and best cut-off values will be
calculated for each separate time point (Day 15 of Cycle 1
and Day 21 of Cycle 2 respectively). Whenever applicable
and possible, baseline values (of 18F-FDG and 18F-FLT and
pharmacokinetics parameters) will be included as separate
(fixed) covariables.
A series of analysis will be performed to study PET im-
aging compared to ceCT, currently considered the ‘gold
standard’. Agreement of test results will be evaluated using
Bland- Altman plots and results will be expressed in terms
of bias and precision measures with corresponding confi-
dence limits. Both ceCT and PET data (i.e. baseline,
decrease) will be associated with PFS and OS by means of
survival model predictive accuracy analysis (cox regression)
to obtain estimates of (time-dependent) sensitivity and
specificity, and (time-dependent) receiver operating charac-
teristic (ROC) curves [58–60]. Survival estimates will be
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plotted in Kaplan-Meier curves and tabulated with 95%
confidence intervals at fixed time points and at its median
(including 95% confidence interval).
Log-rank tests will be used for comparing different groups
with respect to survival outcomes. Cox-proportional hazard
analysis will be used to calculated hazard ratios and to
model survival in the presence of potential imbalances or
confounders.
Discussion
In the majority of irresectable stage IIIc or metastatic
BRAFV600 positive melanoma patients treated with
combined BRAF/MEK inhibitors, metabolic alterations
occur rapid after the initiation of therapy. Molecular
imaging with PET visualizes metabolic activity in tumors
and is a sensitive method to detect alterations in cell
metabolism, even shortly after the start of therapy.
By detecting these metabolic alterations, responders to
BRAF/MEK inhibition might be distinguished from
non-responders at an earlier phase compared with ana-
tomical imaging with ceCT and might predict resistance
which occurs in almost all of these patients.
The REPOSIT study will enroll patients with unresectable
locally advanced stage IIIc or stage IV melanoma as defined
by the American Joint Committee on Cancer (AJCC) classi-
fication v.7. This study will be conducted only in patients
whose melanoma harbors the BRAFV600E or BRAFV600 K
mutation. Patients will be treated with vemurafenib plus
cobimetinib and are monitored with PET/CT to assess the
value of PET imaging in early response monitoring and
resistance prediction. The information obtained from histo-
pathological tissue characterization and pharmacokinetic
analysis will be complementary to the imaging approaches;
together they will allow us to draw a complete picture of
early resistance mechanisms, aiming to make better predic-
tions on the duration of response and development of
resistance to treatment. We expect that the obtained results
of this study will enable the development of personalized
treatment selection strategies that in the future may select
those patients who will have long term benefit from this
treatment and prevent the initiation of an ineffective ther-
apy and accompanying toxicity. Furthermore, this study
may provide further insight in the mechanisms of resistance
to combined BRAF and MEK inhibition.
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